Comparison of a Multidose Powder Inhaler Containing Beclomethasone Dipropionate (BDP) with a BDP Metered Dose Inhaler with Spacer in the Treatment of Asthmatic Patients

Poukkula, Anneli; Alanko, Kristiina; Kilpiö, K.; Knuuttila, Aija; Koskinen, Sirkka; Laitinen, Jukka; Lehtonen, Kaarina; Liippo, K.; Lindqvist, Ari; Lähelmä, Satu; Paananen, M.; Ruotsalainen, E.-M.; Salomaa, Eija-Riitta; Silvasti, M; Suuronen, U.; Toivanen, Petri; Vilkka, Vesa

doi:10.2165/00044011-199816020-00002

Cited by 10 publications

(3 citation statements)

References 13 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…A total of 14 papers 38,41,[43][44][45][46][47][48][54][55][56][57][58][59] describe 15 studies (considering the three-way crossover of Vidgren and colleagues 1994a/b 41 as separate studies). In all, 15 outcomes were available for analysis with a Statistically significant differences were apparent in the baseline characteristics of three of the studies.…”

Section: Dry Powder Inhalers Versus Pmdi ± Spacermentioning

confidence: 99%

Comparison of the effectiveness of inhaler devices in asthma and chronic obstructive airways disease: a systematic review of the literature

Brocklebank

Ram

Wright

et al. 2001

Health Technol Assess

353

197

View full text Add to dashboard Cite

et al. Comparison of the effectiveness of inhaler devices in asthma and chronic obstructive airways disease: a systematic review of the literature. Health Technol Assess 2001;5(26). Health Technology Assessment is indexed in Index Medicus/MEDLINE and Excerpta Medica/ EMBASE. Copies of the Executive Summaries are available from the NCCHTA website (see opposite). NHS R&D HTA Programme T he NHS R&D Health Technology Assessment (HTA) Programme was set up in 1993 to ensure that high-quality research information on the costs, effectiveness and broader impact of health technologies is produced in the most efficient way for those who use, manage and provide care in the NHS. Initially, six HTA panels (pharmaceuticals, acute sector, primary and community care, diagnostics and imaging, population screening, methodology) helped to set the research priorities for the HTA Programme. However, during the past few years there have been a number of changes in and around NHS R&D, such as the establishment of the National Institute for Clinical Excellence (NICE) and the creation of three new research programmes: Service Delivery and Organisation (SDO); New and Emerging Applications of Technology (NEAT); and the Methodology Programme. This has meant that the HTA panels can now focus more explicitly on health technologies ('health technologies' are broadly defined to include all interventions used to promote health, prevent and treat disease, and improve rehabilitation and long-term care) rather than settings of care. Therefore the panel structure has been redefined and replaced by three new panels: Pharmaceuticals; Therapeutic Procedures (including devices and operations); and Diagnostic Technologies and Screening. The HTA Programme will continue to commission both primary and secondary research. The HTA Commissioning Board, supported by the National Coordinating Centre for Health Technology Assessment (NCCHTA), will consider and advise the Programme Director on the best research projects to pursue in order to address the research priorities identified by the three HTA panels. The research reported in this monograph was funded as project number 97/23/02. The views expressed in this publication are those of the authors and not necessarily those of the HTA Programme or the Department of Health. The editors wish to emphasise that funding and publication of this research by the NHS should not be taken as implicit support for any recommendations made by the authors. Criteria for inclusion in the HTA monograph series Reports are published in the HTA monograph series if (1) they have resulted from work commissioned for the HTA Programme, and (2) they are of a sufficiently high scientific quality as assessed by the referees and editors. Reviews in Health Technology Assessment are termed 'systematic' when the account of the search, appraisal and synthesis methods (to minimise biases and random errors) would, in theory, permit the replication of the review by others.

show abstract

Section: Dry Powder Inhalers Versus Pmdi ± Spacermentioning

confidence: 99%

Comparison of the effectiveness of inhaler devices in asthma and chronic obstructive airways disease: a systematic review of the literature

Brocklebank

Ram

Wright

et al. 2001

Health Technol Assess

353

197

View full text Add to dashboard Cite

show abstract

“…Наиболее частыми побочными эффектами были охриплость и неприятные ощущения в горле. При этом в группе пациентов, использовавших изихейлер, отмечена более высокая приверженность к ингалятору [29].…”

Section: обмен опытомunclassified

Inhalation Therapy in Children: Issues and Options

Селимзянова¹,

Промыслова²,

Вишнёва³

2014

Vopr. sovr. pediatr.

View full text Add to dashboard Cite

Ингаляционный способ доставки различных лекар-ственных средств традиционно применяют в медицине: ингаляция обеспечивает быструю доставку препарата в дыхательные пути. Кроме того, она позволяет исполь-зовать более высокие дозы лекарственного средства по сравнению даже с максимально возможными, при-нимаемыми внутрь или парентерально. Известно также, что при ингаляционном введении лекарственных препа-ратов риск системных эффектов значительно ниже, чем при пероральном или инъекционном.Ингаляциями пользовались еще в древнюю эпоху: лечение проводилось парами горячих минеральных источников, лекарственными растениями, ароматиче-скими веществами и т. п.Первым специальным устройством для ингаля-ций стал прибор компрессорного типа, изобретенный J. Sales-Gyrons в 1858 г. Этот прибор, названный небу-лайзером, превращал жидкость в аэрозоль [1]. В после-дующие годы происходило дальнейшее усовершенство-вание систем доставки ингаляционных лекарственных

show abstract

“…2); actually, this sets a significant problem only rarely, as 74% of the preschoolers and almost all the over-6 children are capable of a peak breath rate over 30 l/min. [27]. Adequate specialist's interaction with the patient (parents or legal representatives) is crucial for baseline therapy of bronchial asthma, as treatment usually lasts for a long term.…”

Section: Metered Aerosol and Metered Powder Inhalersmentioning

confidence: 99%

Means of drug delivery in the event of inhalation therapy in children: selection criteria

Селимзянова¹,

Вишнёва²,

Промыслова³

2014

PPh

View full text Add to dashboard Cite

Means of drug delivery in the event of inhalation therapy in children: selection criteria Contacts:Liliya Robertovna Selimzyanova, PhD in Medicine, senior research fellow at the department of standardization and clinical pharmacology of the Scientific Center of Children's Health, assistant at the department of pediatrics and pediatric rheumatology of the Sechenov First Moscow State Medical University Address: 2/1 Lomonosovskiy Av., Moscow, 119991; tel.: +7 (495)

show abstract

Comparison of a Multidose Powder Inhaler Containing Beclomethasone Dipropionate (BDP) with a BDP Metered Dose Inhaler with Spacer in the Treatment of Asthmatic Patients

Abstract: In conclusion, the novel powder inhaler was well tolerated and at least equally effective compared with the conventional MDI-spacer combination in the treatment of asthma with BDP. However, in everyday use the patients clearly favoured the powder inhaler.

Cited by 10 publications

References 13 publications

Comparison of the effectiveness of inhaler devices in asthma and chronic obstructive airways disease: a systematic review of the literature

Comparison of the effectiveness of inhaler devices in asthma and chronic obstructive airways disease: a systematic review of the literature

Inhalation Therapy in Children: Issues and Options

Means of drug delivery in the event of inhalation therapy in children: selection criteria

Contact Info

Product

Resources

About